NCT06213298View on ClinicalTrials.gov

Effect of Kava on Anxiety and Stress in Cancer Survivors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 1, 2026

Conditions
KavaAnxietyStressCancerDepressionSleep
Interventions
DRUG

Kava

75 mg kavalactones

DIETARY_SUPPLEMENT

Placebo

Placebo capsule

Trial Locations (1)

55455

RECRUITING

Masonic Cancer Center, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER